A survey conducted on 63 medical experts from 13 countries of Europe on their opinions about Augmentation Therapy (AT) as part of treatment guidelines for alpha-1 antitrypsin deficiency (AATD) associated lung disease has found that there is a considerable variability in the opinions. The survey also found that decisions about initiating AT take into consideration several variables not included in the current recommendations described in the guidelines. The experts said that they were asked to rank the importance of 11 identified factors related with the prescription of AT, which yielded the results that a significant number of patients with genotype PiSZ and almost 10 percent PiMZ were recommended to initiate AT despite the lack of evidence of efficacy in these genotypes.